Sequana Medical NV, a commercial stage medical device company, focuses on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites, and other fluid imbalance disorders.
The last earnings update was 133 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Sequana Medical. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Sequana Medical's earnings available for a low price, and how does
this compare to other companies in the same industry?
Sequana Medical is not considered high growth as it is expected to be loss making for the next 1-3 years.
Sequana Medical's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Sequana Medical's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Mr. Ian Crosbie is the Chief Executive Officer of Sequana Medical NV. Mr. Crosbie has been the Chief Executive Officer of Sequana Medical AG since December 22, 2016. He served as Chief Financial Officer of Sequana Medical AG from July 1, 2016 to December 22, 2016. He served as Chief Financial Officer at Global Consolidated Aesthetics Limited. Mr. Crosbie served as the Chief Financial Officer of GC Aesthetics PLC since January 2015 and served as its Principal Accounting Officer. He served as Senior Vice President of Corporate Development at Circassia Limited since 2013. Mr. Crosbie joined Circassia Limited on November 2013 and worked until December 2014. He has extensive senior-level strategic advisory experience in the life sciences industry. He served as Head of Healthcare Investment Banking at Jefferies Group LLC (formerly Jefferies Group, Inc.) since March 18, 2008. He served as a Managing Director in the healthcare investment banking group at Jefferies International Limited from March 2008 to April 2013. He served as Director of Healthcare Investment Banking at Deutsche Bank. He served as Managing Director at Ferghana Partners Group, a founder and Partner at Gargoyle Partners and a Director in the healthcare investment banking group at Deutsche Bank AG. He was founder of Gargoyle Partners in 2003 and joined FPG through the combination of the two firms in 2005. Together with Rawle Michelson, Mr. Crosbie was responsible for FPG’s activities in Europe across all product areas. He was Founder of Gargoyle Associates Ltd. and served as its Executive Officer. He was an Independent Corporate Consultant from May 2013 to October 2013. He is an experienced healthcare investment banker having worked for more than twelve years across all sectors of the industry, including pharmaceuticals, biotech, life sciences enabling tools, devices, diagnostics and services. He has a track record in M&A and equity & debt capital raising. Mr. Crosbie began his career with Bain & Co. as a Strategic Management Consultant both in London and California, before moving into investment banking with Baring Brothers in London. He then joined the healthcare team of Alex. Brown & Sons and was one of the original members of that team in Europe. Following the acquisition by Bankers Trust and Deutsche Bank. He served as co-head of Deutsche Bank’s European healthcare investment banking group, covering both financing and advisory products and all sectors of the industry. He served as an Equity Analyst of Deutsche Bank AG, Research Division. In 2003, Mr. Crosbie joined Rawle Michelson to found Gargoyle Partners and was a leading player in establishing the Rawle Michelson’s presence in the healthcare sector. He served as a Second Lieutenant in the 32ndArmoured Engineer Regiment of the British Army Mr. Crosbie received his MA (Oxon) in Engineering, Economics and Management from Oxford University.
Insufficient data for Ian to compare compensation growth.
Insufficient data for Ian to establish whether their remuneration is reasonable compared to companies of similar size in United Kingdom of Great Britain and Northern Ireland.
CEO & Executive Director
Kirsten Van Bockstaele
Chief Financial Officer
Director of Investor Relations
Chief Medical Officer
Chief Commercial Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Sequana Medical board of directors is less than 3 years, this suggests a new board.
Board of Directors
CEO & Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Sequana Medical NV, a commercial stage medical device company, focuses on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites, and other fluid imbalance disorders. Its products include alfapump, a treatment solution for the long-term management of liver refractory ascites and malignant ascites; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with volume overload due to heart failure. The company was founded in 2006 and is headquartered in Ghent, Belgium.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.